# Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Canonical URL: https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-fiscal-2026-second-quarter-results
Ticker: ARWR
Company: Arrowhead Pharmaceuticals
Source: Arrowhead Pharmaceuticals
Published: 2026-05-07 20:01 EST
Original Source URL: https://ir.arrowheadpharma.com
## Summary

- Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

## Article Body
- Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.
## Recent Company News
- 2026-06-02 11:30 EST — [Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-participate-in-upcoming-june-2026-events) — Source: Arrowhead Pharmaceuticals
- 2026-05-27 11:00 EST — [Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-clinical-data-on-rnai-based-obesity-and-mash-candidate-aro-inhbe-at-easl-2026) — Source: Arrowhead Pharmaceuticals
- 2026-05-26 14:00 EST — [Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-positive-clinical-cardiometabolic-data-at-the-94th-european-atherosclerosis-society-eas-congress) — Source: Arrowhead Pharmaceuticals
- 2026-05-07 20:01 EST — [Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-fiscal-2026-second-quarter-results) — Source: Arrowhead Pharmaceuticals
- 2026-05-05 12:00 EST — [Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-licenses-clinical-mash-program-targeting-pnpla3-to-madrigal-pharmaceuticals) — Source: Arrowhead Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)